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In this study, 3-alkyl(aryl)-4-amino-4,5-dihydro-1H-1,2,4-triazol-5-ones have been reacted with 3-methoxy-4-
isobutyryloxybenzaldehyde 2 to afford the corresponding nine new 3-alkyl(aryl)-4-(3-methoxy-4-
isobutyryloxybenzylideneamino)-4,5-dihydro-1H-1,2,4-triazol-5-ones 3. Then, the acetylation reactions of compounds 3 
have been investigated and 4 type compounds have been obtained. The compounds 3 have also been treated with 
morpholine/1-methylpiperazine in the presence of formaldehyde according to the Mannich reaction to synthesize 1-
(morpholine-4-yl-methyl)-3-alkyl(aryl)-4-(3-methoxy-4-isobutyryloxy-benzylideneamino)-4,5-dihydro-1H-1,2,4-triazol-5-
ones 5, and 1-(1-methylpiperazin-4-yl-methyl)-3-alkyl(aryl)-4-(3-methoxy-4-isobutyryloxybenzylideneamino)-4,5-dihydro-
1H-1,2,4-triazol-5-ones 6, respectively. The structures of twenty four new compounds have been characterized by IR, 1H 
and 13C NMR and MS spectroscopic methods. In addition, the newly synthesized compounds have been screened for their 
antimicrobial activities. Furthermore, these twenty four new compounds have been analyzed for their in vitro potential 
antioxidant activities by three different methods. 
Keywords: 4,5-dihydro-1H-1,2,4-triazol-5-one, Schiff base, Mannich base, acetylation, antimicrobial activity, antioxidant 
activity 
Antibiotic resistance is recognized as one of the 
leading public health problems worldwide. The rapid 
emergence and prevalence of antibiotic resistant 
pathogens requires a serious effort to identify, 
develop and design new antibiotics
1
. Considering the 
importance of heterocyclic compounds in medicinal 
chemistry, design and synthesis of novel heterocycles 
can play a significant role in this regard. 
Triazoles are heterocyclic compounds that contain 
three nitrogen atoms. Some of the modern drugs which 
containing a triazole moiety are alprazolam, triazolam, 
estazolam (hypnotic, sedative, tranquilizer), trazodone 
(antidepressant, anxiolytic), trapidil (hypotensive), 
terconazole (antifungal), hexaconazole (antifungal), 
etizolam (amnesic, anxiolytic, anticonvulsant, hypnotic, 
sedative and skeletal muscle relaxant), rilmazafon 
(hypnotic, anxiolytic) and rizatriptan (antimigrane 
agent)
2
. 1,2,4-Triazole and 4,5-dihydro-1H-1,2,4-triazol-
5-one derivatives have been found to have a broad 
spectrum of biological activities
3-9
. 
The classical Mannich reaction, a three-component 
condensation between structurally diverse substrates 
containing at least one active hydrogen atom, an 
aldehyde component and an amine reagent leads to a 
class of compounds known as Mannich bases
10
. 
Mannich bases have applications in the pharmaceutical 
field and in other industries, such as the petroleum, the 
cosmetics, the dyes and the food industries, etc. The 
principal advantage of the Mannich reaction is that it 
enables two different molecules to be bonded together in 
one step
11
. Mannich bases obtained from 1,2,4-triazole 
derivatives are reported to possess biological activities 
such as antifungal
12
, antioxidant
13,14
, antilipase
15
, 
antibacterial
15-17
 properties. 
Considering about the development of new hetero 
moieties by combining potential biological active 
scaffolds, an attempt was made here to obtain 1,2,4-
triazoles bearing morpholine and 1-methylpiperazine 
ring then to evaluate their antimicrobial and 
antioxidant activity. 
 
Results and Discussion 
In the present study, nine new 3-alkyl(aryl)-4-(3-
methoxy-4-isobutyryloxybenzylidene-amino)-4,5-
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dihydro-1H-1,2,4-triazol-5-ones, five new 1-acetyl-3-
alkyl(aryl)-4-(3-methoxy-4-isobutyryloxybenzyli 
deneamino)-4,5-dihydro-1H-1,2,4-triazol-5-ones, five 
new 1-(morpholine-4-yl-methyl)-3-alkyl(aryl)-4-(3-
methoxy-4-isobutyryloxy-benzylideneamino)-4,5-
dihydro-1H-1,2,4-triazol-5-ones and five new 1-(1-
methylpiperazine-4-yl-methyl)-3-alkyl(aryl)-4-(3-
methoxy-4-isobutyryloxybenzylidene-amino)-4,5-
dihydro-1H-1,2,4-triazol-5-ones synthesized. For that 
purpose, 3-methoxy-4-isobutyryloxybenzaldehyde
18
 2 
was synthesized by the reactions of 4-hydroxy-3-
methoxybenzaldehyde with isobutyryl chloride by 
using triethylamine. The 3-alkyl(aryl)-4-(3-methoxy-
4-isobutyryloxybenzylideneamino)-4,5-dihydro-1H-1, 
2,4-triazol-5-ones 3a-i were obtained from the 
reactions of compounds 3-alkyl(aryl)-4-amino-4,5-
dihydro-1H-1,2,4-triazol-5-ones 1a-i with 3-methoxy-
4-isobutyryloxy benzaldehyde 2. Then, the reactions 
of compounds 3a, 3b, 3d, 3e and 3g with acetic 
anhydride were investigated and 4 type compounds 
were prepared. Later, synthesized 3 type compounds 
were treated with morpholine / 1-methylpiperazine in 
the presence of formaldehyde according to the 
Mannich reaction to synthesized 5a, 5b, 5d, 5e, 5g / 
6a, 6b, 6d, 6e, 6g respectively (Scheme I). 
The structures of nine new Schiff bases 3, five  
new N-acetyl derivatives 4, ten new N-Mannich base 
derivatives 5 and 6 of 3 type compounds were identified 
by using IR, 
1
H NMR, 
13
C NMR, and MS data. 
 
Antimicrobial Activity 
The synthesized compounds were screened for their 
antimicrobial activities, and some of them were found to 
possess significant activity (Table I). The compounds 
3a, 3b, 3d and 3i did not display any antimicrobial 
activity against to all of tested microorganisms. Mannich 
bases were particularly appeared most active at a better 
level compared to Schiff bases. 
 
Antioxidant Activity 
The antioxidant activities of twenty four new 
compounds 3a-i, 4a, 4b, 4d, 4e, 4g, 5a, 5b, 5d, 5e, 
5g, 6a, 6b, 6d, 6e and 6g were determined. Several 
methods have been used to determine antioxidant 
activities and the methods used in the study are given 
below: 
 
Total reductive capability using the potassium 
ferricyanide reduction method 
The reductive capabilities of compounds were 
assessed by the extent of conversion of the Fe
3+
 / 
ferricyanide complex to the Fe
2+
 / ferrous form. The 
reducing powers of the compounds were observed at 
different concentrations, and results were compared 
with BHT and α-tocopherol. It has been observed that 
 
 
Scheme I 
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the reducing capacity of a compound may serve as a 
significant indicator of its potential antioxidant 
activity
19
. The antioxidant activity of putative 
antioxidant has been attributed to various 
mechanisms, among which are prevention chain 
initiation, binding of transition metal ion catalyst, 
decomposition of peroxides, prevention of continued 
hydrogen abstraction, reductive capacity and  
radical scavenging
20
. In the study, examined 
compounds did not show the reductive activities.  
In other words, all the amount of the compounds 
showed lower absorbance than standard antioxidants 
such as BHT and α-tocopherol. Hence, no activities 
were observed to reduce metal ions complexes to their 
lower oxidation state or to take part in any electron 
transfer reaction. 
DPPH
.
Radical Scavenging Activity 
The model of scavenging the stable DPPH radical 
model is a widely used method to evaluate antioxidant 
activities in a relatively short time compared with 
other methods. The effect of antioxidants on DPPH 
radical scavenging was thought to be due to their 
hydrogen donating ability
21
. DPPH is a stable  
free radical and accepts an electron or hydrogen 
radical to become a stable diamagnetic molecule
22
. 
The reduction capability of DPPH radicals was 
determined by decrease in its absorbance at 517 nm 
induced by antioxidants. The absorption maximum of 
a stable DPPH radical in ethanol was at 517 nm.  
The decrease in absorbance of DPPH radical was 
caused by antioxidants because of reaction between 
antioxidant molecules and radical, progresses, which 
resulted in the scavenging of the radical by hydrogen 
donation. It is visually noticeable as a discoloration 
from purple to yellow. Hence, DPPH
.
 is usually used 
as a substrate to evaluate antioxidative activity of 
antioxidants
23
. Antiradical activities of compounds 
and standard antioxidants such as BHT, BHA and  
α-tocopherol were determined by using DPPH. 
method. Scavenging effect values of the compounds 
with BHT, BHA and α-tocopherol at different 
concentrations are respectively given in Figure 1 and 
Figure 2. The newly synthesized compounds which 
demonstrate increasing scavenging effect with 
growing concentration, were plotted on the graphs. 
The metal chelating effect of these compounds and 
references decreased in order of α-tocopherol > BHA 
> BHT > 6a > 3c > 3e > 5b > 3a > 3b > 3i > 6d, 
which were 74.9, 74.3, 65.8, 19.3, 16.0, 12.4, 9.6, 9.3, 
8.2, 7.2, 5.3 (%), at the highest concentration, 
respectively. 
 
Ferrous Iron Chelating Activity 
The chelating effect towards ferrous ions by the 
compounds and standards was determined. Ferrozine 
can quantitatively form complexes with Fe
2+
. In the 
presence of chelating agents, the complex formation 
is disrupted with the result that the red colour of  
the complex is decreased. Measurement of colour 
reduction therefore allows estimation of the chelating 
activity of the coexisting chelator
24
. Transition metals 
have pivotal role in the generation oxygen free 
radicals in living organism. The ferric iron (Fe
3+
) is 
the relatively biologically inactive form of iron. 
However, it can be reduced to the active Fe
2+
, 
depending on condition, particularly pH
25
 and oxidized 
back through Fenton type reactions with the production 
Table I — Antimicrobial activity of the compounds 3, 4, 5 and 6 
Compd 
Microorganisms and inhibition zone (mm) 
Bs Bc Pa Kp Sa Ec 
3a − − − − − − 
3b − − − − − − 
3c 16 12 7 − − − 
3d − − − − − − 
3e 11 − 9 − − 12 
3f 8 11 11 10 12 14 
3g 13 17 11 − − 10 
3h 13 − − 8 − − 
3i − − − − − − 
4a − − 13 12 8 16 
4b 11 11 8 11 8 14 
4d 7 10 12 − 10 12 
4e 10 7 − 9 10 9 
4g 8 8 − 7 8 9 
5a 19 19 18 21 22 23 
5b 17 16 16 13 15 16 
5d 18 17 17 20 17 21 
5e 18 14 18 21 19 17 
5g 14 19 16 14 18 20 
6a 23 25 26 24 24 26 
6b 22 24 26 25 26 26 
6d 21 22 23 26 22 18 
6e 19 19 23 25 14 21 
6g 11 13 20 14 11 15 
Amp. 33 36 36 35 37 34 
Neo. 17 17 17 16 13 16 
Str. 12 12 12 11 21 10 
Bs: Bacillus subtilis (ATCC-11774), Bc: Bacillus cereus  
(ATCC-11778), Pa: Pseudomonas aeruginosa (ATCC-27853), 
Kp: Klebsiella pneumoniae (ATCC-4352) Sa: Staphylococcus 
aureus (ATCC-6538), Ec: Escherichia coli (ATCC-25922), 
Amp.: Ampicillin (3261), Neo.: Neomycin (3360), Str.: 
Streptomycin (3385). 
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of hydroxyl radical or Haber-Weiss reactions with 
superoxide anions. The production of these radicals 
may lead to lipid peroxidation, protein modification 
and DNA damage. Chelating agents may not activate 
metal ions and potentially inhibit the metal-dependent
 
processes
26
. Also, the production of highly active 
ROS such as O2
.−
, H2O2 and OH
.
 is also catalyzed by 
free iron though Haber-Weiss reactions: 
 
O
.
2 + H2O2 → O2 + OH
−
 + OH
. 
Among the transition metals, iron is known as the 
most important lipid oxidation pro-oxidant due to its 
high reactivity. The ferrous state of iron accelerates 
lipid oxidation by breaking down the hydrogen and 
lipid peroxides to reactive free radicals via the Fenton 
reactions: Fe
2+
 + H2O2 → Fe
3+
 + OH
−
 + OH
.
 
Fe
3+
 ion also produces radicals from peroxides, 
even though the rate is tenfold less than that of Fe
2+
 
ion, which is the most powerful pro-oxidant among 
the various types of metal ions
27
. Ferrous ion 
chelating activities of the compounds 3, 4, 5, 6, 
EDTA and α-tocopherol are respectively shown in 
Figure 3, Figure 4 and Figure 5. 
In this study, metal chelating capacity was significant 
since it reduced the concentrations of the catalyzing 
transition metal. It was reported that chelating agents 
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Figure 1 — Scavenging effect of compounds 3a-c, 3e, 3i, BHT, BHA and α-tocopherol at different concentrations (12.5-25-37.5 µg/mL) 
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Figure 2 — Scavenging effect of compounds 5b, 6a, 6d, BHT, BHA and α-tocopherol at different concentrations (12.5-25-37.5 µg/mL) 
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that form σ-bonds with a metal are effective as 
secondary antioxidants because they reduce the redox 
potential thereby stabilizing the oxidized form of metal 
ion
28
. The data obtained from Figure 3, Figure 4 and 
Figure 5 reveal that the compounds demonstrate a 
marked capacity for iron binding, except 3c-e, 
suggesting that their action as peroxidation protectors 
may be related to their iron binding capacity. Mannich 
bases were found to be most active when compared to 
Schiff bases for all concentrations. 
Experimental Section 
Chemical reagents used in this study were 
purchased from Merck AG, Aldrich and Fluka. The 
starting materials 1a-i were prepared from the reactions 
of the corresponding ester ethoxycarbonylhydrazones 
with an aqueous solution of hydrazine hydrate as 
described in the literature
29,30
. Melting points were 
determined in open glass capillaries by using a Stuart 
SMP-30 melting point apparatus and are uncorrected. 
The IR spectra were obtained by an ALPHA-P 
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Figure 3 — Metal chelating effect of different amount of the compounds 3, 4, EDTA and α-tocopherol on ferrous ions 
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Figure 4 — Metal chelating effect of different amount of the compounds 5, EDTA and α-tocopherol on ferrous ions 
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BRUKER FT-IR spectrometer. 
1
H and 
13
C NMR 
spectra were recorded in DMSO-d6 with TMS as 
internal standard using a Bruker 400 NMR spectrometer 
at 400 MHz for 
1
H and 100 MHz for 
13
C with TMS  
as internal standard. Electrospray ionisation mass 
spectrometry (ESI-MS) was performed on a TSQ 
Quantum Access Max Triple Stage Quadrupole Mass 
Spectrometer. 
 
General procedure for the synthesis of compounds 3 
4-Hydroxy-3-methoxybenzaldehyde (0.01 mol) 
dissolved in ethyl acetate (20 mL) was treated with 
isobutyryl chloride (0.01 mol) and to this solution was 
slowly added triethylamine (0.01 mol) with stirring at 
0-5°C. The process of stirring continued for 2 h, and 
then the mixture was refluxed for 3 h and filtered. The 
filtrate was evaporated in vacuo, and the crude 
product was washed with water and recrystallized 
from ethanol to afford compound 2
18
, m.p.64°C. IR: 
2849 and 2737 (CHO), 1759, 1697 (C=O), 1232 
(COO) cm
−1
; 
1
H NMR (DMSO-d6): δ 1.25 (d, 6H, 
2CH3 J = 6.80 Hz), 2.86 (hept, 1H, CH; J = 6.80 Hz), 
3.87 (s, 3H, OCH3), 7.35 (d, 1H, ArH; J = 7.60 Hz), 
7.60 (td, 1H, ArH; J = 8.00 Hz, 1.60 Hz), 7.64 (d, 1H, 
ArH; J = 1.60 Hz), 9.98 (s, 1H, CHO); 
13
C NMR 
(DMSO-d6): δ 18.77 (2CH3), 33.04 (CH), 56.01 
(OCH3), [111.50; 123.31(2C); 132.26; 144.50; 
151.59] (ArC), 174.31 (COO), 191.80 (CHO). The 
corresponding compound 1 (0.01 mol) was dissolved 
in acetic acid (20 mL) and treated with 3-methoxy-4-
isobutyryloxy benzaldehyde 2 (0.01 mol). The 
mixture was refluxed for 2 h and then the solvent 
evaporated at 50-55°C in vacuo. Several recrystallizations 
of the residue from an appropriate solvent gave pure 
compounds 3-alkyl(aryl)-4-(3-methoxy-4-isobutyryloxy-
benzylideneamino)-4,5-dihydro-1H-1,2,4-triazol-5-
ones 3 as colorless crystals. 
3-Methyl-4-(3-methoxy-4-isobutyryloxy benzylidene 
amino)-4,5-dihydro-1H-1,2,4-triazol-5-one, 3a: Yield 
3.09 g (97.4%). m.p. 159°C. IR: 3170 (NH), 3039 
(C=CH), 1750, 1707 (C=O), 1605, 1581 (C=N), 1222 
(COO) cm
−1
; 
1
H NMR (DMSO-d6): δ 1.25 (d, 6H, 
2CH3; J = 6.92 Hz), 2.30 (s, 3H, CH3), 2.84 (hept, 1H, 
CH; J = 6.96 Hz), 3.84 (s, 3H, OCH3), 7.22 (d, 1H, 
ArH; J = 8.12 Hz), 7.46 (dd, 1H, ArH; J = 8.20Hz, 
0.80 Hz), 7.58 (d, 1H, ArH; J = 1.60 Hz), 9.72 (s, 1H, 
N=CH), 11,85 (s, 1H, NH); 
13
C NMR (DMSO-d6): δ 
11.55 (CH3), 19.19 (2CH3), 33.65 (CH), 56.43 
(OCH3), [111.82; 120.88; 123.79; 132.81; 142.33; 
151.73] (ArC), 144.74 (Triazole C3), 151.68 (N=CH), 
153.31 (Triazole C5), 174.70 (COO); MS (70 eV): m/z 
(%) 115.11 (% 16), 319.11 (M+1)
+
 (% 52), 360.11 
(100), 637.25 (2M+1, 84). 
3-Ethyl-4-(3-methoxy-4-isobutyryloxybenzylidene 
amino)-4,5-dihydro-1H-1,2,4-triazol-5-one, 3b: Yield  
3.19 g (96.3%). m.p. 169°C. IR: 3169 (NH), 3052 
(C=CH), 1762, 1701 (C=O), 1597 (C=N), 1232 
(COO) cm
−1
; 
1
H NMR (DMSO-d6): δ 1.21 (t, 3H, 
CH2CH3; J = 7.60 Hz), 1.24 (d, 6H, 2CH3; J = 7.20 Hz), 
2.70 (q, 2H, CH2CH3; J = 7.60 Hz), 2.84 (hept, 1H, CH; 
J = 7.20 Hz), 3.83 (s, 3H, OCH3), 7.21 (d, 1H, ArH;  
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Figure 5 — Metal chelating effect of different amount of the compounds 6, EDTA and α-tocopherol on ferrous ions 
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J = 8.40 Hz), 7.45 (dd, 1H, ArH; J = 8.20 Hz,  
1.60 Hz), 7.56 (d, 1H, ArH; J = 1.60 Hz), 9.71 (s, 1H, 
N=CH), 11,84 (s, 1H, NH); 
13
C NMR (DMSO-d6): δ 
9.98 (CH2CH3), 18.48 (CH2CH3), 18.72 (2CH3), 33.17 
(CH), 56.00 (OCH3), [111.47; 120.34; 123.36; 
132.37; 141.90; 151.35] (ArC), 148.04 (Triazole C3), 
151.29 (N=CH), 153.00 (Triazole C5), 174.20 (COO); 
MS (70 eV): m/z (%) 115.14 (8), 333.09 (M+1, 52), 
374.12 (96), 665.29 (2M+1, 100). 
3-n-Propyl-4-(3-methoxy-4-isobutyryloxy 
benzylideneamino)-4,5-dihydro-1H-1,2,4-triazol-5-one, 
3c: Yield 3.24 g (93.9%). m.p. 133°C. IR: 3169 (NH), 
3068 (C=CH), 1754, 1703 (C=O), 1597, 1582 (C=N), 
1232 (COO) cm
−1
; 
1
H NMR (DMSO-d6): 0.96 (t, 3H, 
CH2CH2CH3; J = 7.60 Hz), 1.24 (d, 6H, 2CH3;  
J = 7.20 Hz), 1.70 (sext, 2H, CH2CH2CH3; J = 7.20 Hz), 
2.66 (t, 2H, CH2CH2CH3; J = 7.20 Hz), 2.84 (hept, 
1H, CH; J = 7.20 Hz), 3.83 (s, 3H, OCH3), 7.21  
(d, 1H, ArH; J = 8.00 Hz), 7.45 (dd, 1H, ArH;  
J = 8.40 Hz, 1.60 Hz), 7.56 (d, 1H, ArH; J = 2.00 Hz), 
9.71 (s, 1H, N=CH), 11,84 (s, 1H, NH); 
13
C NMR 
(DMSO-d6): δ 13.48 (CH2CH2CH3), 18.73 (2CH3), 
18.95 (CH2CH2CH3), 26.69 (CH2CH2CH3), 33.17 
(CH), 55.98 (OCH3), [111.49; 120.30; 123.39; 
132.38; 141.90; 151.28] (ArC), 146.92 (Triazole C3), 
151.28 (N=CH), 152.98 (Triazole C5), 174.21 (COO); 
MS (70 eV): m/z (%) 115.12 (22), 143.07 (8), 347.08 
(M+1, 40), 388.15 (62), 693.33 (2M+1, 100). 
3-Benzyl-4-(3-methoxy-4-isobutyryloxy 
benzylideneamino)-4,5-dihydro-1H-1,2,4-triazol-5-
one, 3d: Yield 3.85 g (97.8%); m.p. 154°C. IR: 3154 
(NH), 3073 (C=CH), 1758, 1704 (C=O), 1599, 1575 
(C=N), 1227 (COO), 758,702 (monosubstituted 
benzenoid ring) cm
−1
; 
1
H NMR (DMSO-d6): δ 1.24  
(d, 6H, 2CH3; J = 6.80 Hz), 2.83 (hept, 1H, CH;  
J = 6.80 Hz), 3.85 (s, 3H, OCH3), 4.08 (s, 2H, CH2Ph), 
7.19 (d, 1H, ArH; J = 8.00 Hz), 7.22-7.24 (m, 1H, 
ArH), 7.29-7.36 (m, 4H, ArH), 7.37 (dd, 1H, ArH;  
J = 8.00 Hz, 1.60 Hz), 7.49 (d, 1H, ArH; J = 1.60 Hz), 
9.67 (s, 1H, N=CH), 11,99 (s, 1H, NH); 
13
C NMR 
(DMSO-d6): δ 18.72 (2CH3), 31.22 (CH2Ph), 33.17 
(CH), 55.98 (OCH3), [110.66; 121.00; 123.32; 132.32; 
141.94; 151.26] (ArC), [126.69; 128.44(2C); 128,70 
(2C); 135.87] (ArC linked C-3), 146.20 (Triazole C3), 
151.20 (N=CH), 152.38 (Triazole C5), 174.21 (COO); 
MS (70 eV): m/z (%) 115.13 (86), 143.04 (38), 395.10 
(M+1, 40), 436.12 (26), 789.30 (2M+1, 100). 
3-p-Methylbenzyl-4-(3-methoxy-4-isobutyryloxy 
benzylideneamino)-4,5-dihydro-1H-1,2,4-triazol-5-
one, 3e: Yield 3.99 g (97.9%). m.p. 151°C. IR: 3167 
(NH), 3072 (C=CH), 1750, 1709 (C=O), 1595, 1575 
(C=N), 1238 (COO), 865 (1,4-disubstituted benzenoid 
ring) cm
−1
; 
1
H NMR (DMSO-d6): δ 1.24 (d, 6H, 
2CH3; J = 6.80 Hz), 2.24 (s, 3H, PhCH3), 2.83 (hept, 
1H, CH; J = 6.80 Hz), 3.83 (s, 3H, OCH3), 4.01  
(s, 2H, CH2Ph), 7.11 (d, 2H, ArH; J = 8.00 Hz),  
7.19 (d, 2H, ArH; J = 8.00 Hz), 7.21 (d, 1H, ArH;  
J = 8.00 Hz), 7.38 (dd, 1H, ArH; J = 8.00 Hz,  
1.60 Hz), 7.49 (d, 1H, ArH; J = 1.60 Hz), 9.66 (s, 1H, 
N=CH), 11,96 (s, 1H, NH); 
13
C NMR (DMSO-d6): δ 
18.73 (2CH3), 20.57 (PhCH3), 30.83 (CH2Ph), 33.17 
(CH), 55.97 (OCH3), [110.64; 121.02; 123.33; 132.34; 
141.93; 151.76] (ArC), [128.57(2C); 129.01(2C); 
132.75; 135.76] (ArC linked C-3), 146.35 (Triazole C3), 
151.21 (N=CH), 152.33 (Triazole C5), 174.22 (COO); 
MS (70 eV): m/z (%) 115.10 (14), 143.03 (8), 395.10 
(M+1, 100), 450.17 (26), 817.39 (2M+1, 66). 
3-p-Methoxybenzyl-4-(3-methoxy-4-isobutyryloxy 
benzylideneamino)-4,5-dihydro-1H-1,2,4-triazol-5-
one, 3f: Yield 3.94 g (94.3%); m.p. 171°C. IR: 3163 
(NH), 3031 (C=CH), 1759, 1695 (C=O), 1611, 1581 
(C=N), 1245 (COO), 836 (1,4-disubstituted benzenoid 
ring) cm
−1
;
 1
H NMR (DMSO-d6): δ 1.24 (d, 6H, 
2CH3; J=7.20 Hz), 2.84 (hept, 1H, CH; J =7.20 Hz), 
3.70 (s, 3H, p-OCH3), 3.84 (s, 3H, OCH3), 3.99  
(s, 2H, CH2Ph), 6.87 (d, 2H, ArH; J=8.80 Hz), 7.20 
(d, 1H, ArH; J=8.40 Hz), 7.24 (d, 2H, ArH; J=8.40 
Hz), 7.39 (dd, 1H, ArH; J=8.40 Hz, 1.60 Hz), 7.51  
(d, 1H, ArH; J=1.60 Hz), 9.67 (s, 1H, N=CH), 11,95 
(s, 1H, NH); 
13
C NMR (DMSO-d6): δ 18.73 (2CH3), 
30.34 (CH2Ph), 33.17 (CH), 50.00 (p-OCH3), 56.00 
(OCH3), [110.74; 120.97; 123.34; 132.35; 141.93; 
151.28] (ArC), [113.87(2C); 127.62; 129.76(2C); 
158.07] (ArC linked C-3), 146.51 (Triazole C3), 
151.22 (N=CH), 152.42 (Triazole C5), 174.23 (COO); 
MS (70 eV): m/z (%) 115.09 (44), 143.12 (100), 
425.12 (M+1, 86), 466.12 (22), 849.36 (2M+1, 48). 
3-p-Chlorobenzyl-4-(3-methoxy-4-isobutyryloxy 
benzylideneamino)-4,5-dihydro-1H-1,2,4-triazol-5-
one, 3g: Yield 4.16 g (97.3%). m.p. 177°C. IR: 3169 
(NH), 3061 (C=CH), 1755, 1700 (C=O), 1598, 1578 
(C=N), 1267 (COO), 852 (1,4-disubstituted benzenoid 
ring) cm
−1
; 
1
H NMR (DMSO-d6): δ 1.24 (d, 6H, 
2CH3; J = 6.80 Hz), 2.84 (hept, 1H,CH; J = 6.80 Hz), 
3.83 (s, 3H, OCH3), 4.09 (s, 2H, CH2Ph), 7.20 (d, 2H, 
ArH; J = 8.00 Hz), 7.34-7.37 (m, 3H, ArH), 7.38 (dd, 
1H, ArH; J = 8.40 Hz, 2.00 Hz), 7.48 (d, 1H, ArH;  
J = 1.60 Hz), 9.67 (s, 1H, N=CH), 12.01 (s, 1H, NH); 
13
C NMR (DMSO-d6): δ 18.72 (2CH3), 30.52 
(CH2Ph), 33.17 (CH), 55.99 (OCH3), [110.73; 120.99; 
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123.34; 132.27; 141.97; 151.27] (ArC), [128.38 (2C); 
130.62 (2C); 131.40; 134.87] (ArC linked C-3), 145.86 
(Triazole C3), 151.19 (N=CH), 152.54 (Triazole C5), 
174.21 (COO); MS (70 eV): m/z (%) 115.11 (100), 
143.10 (74), 429.04 (M+1, 26), 470.09 (10). 
3-m-Chlorobenzyl-4-(3-methoxy-4-isobutyryloxy 
benzylideneamino)-4,5-dihydro-1H-1,2,4-triazol-5-
one, 3h: Yield 4.08 g (95.3%). m.p. 179°C. IR: 3130 
(NH), 3052 (C=CH), 1755, 1709 (C=O), 1595, 1574 
(C=N), 1267 (COO), 792 (1,3-disubstituted benzenoid 
ring) cm
−1
; 
1
H NMR (DMSO-d6): δ 1.24 (d, 6H, 2CH3;  
J = 6.80 Hz), 2.83 (hept, 1H, CH; J = 6.80 Hz), 3.84  
(s, 3H, OCH3), 4.11 (s, 2H, CH2Ph), 7.20 (d, 1H, ArH;  
J = 8.00 Hz), 7.28-7.35 (m, 3H, ArH), 7.38 (dd, 1H, 
ArH; J = 8.00 Hz, 1.60 Hz), 7.44-7.45 (m, 1H, ArH), 
7.50 (d, 1H, ArH; J = 1.60 Hz), 9.67 (s, 1H, N=CH), 
12.01 (s, 1H, NH); 
13
C NMR (DMSO-d6): δ 18.72 
(2CH3), 30.74 (CH2Ph), 33.17 (CH), 56.00 (OCH3), 
[110.66; 121.07; 123.32; 132.25; 141.99; 151.29] (ArC), 
[126.75; 127.48; 128.76; 130.28; 132.95; 138.30] (ArC 
linked C-3), 145.69 (Triazole C3), 151.17 (N=CH), 
152.56 (Triazole C5), 174.20 (COO); MS (70 eV): m/z 
(%) 115.12 (100), 143.12 (76), 429.16 (M+1, 16), 
470.13 (8). 
3-Phenyl-4-(3-methoxy-4-isobutyryloxybenzylidene 
amino)-4,5-dihydro-1H-1,2,4-triazol-5-one, 3i: Yield 
3.69 g (97.2%); m.p. 172°C. IR: 3159 (NH), 3056 
(C=CH), 1754, 1700 (C=O), 1584 (C=N), 1264 
(COO), 771 and 694 (monosubstituted benzenoid 
ring) cm
−1
; 
1
H NMR (DMSO-d6): δ 1.24 (d, 6H, 
2CH3; J = 7.20 Hz), 2.84 (hept, 1H, CH; J = 7.20 Hz), 
3.81 (s, 3H, OCH3), 7.23 (d, 1H, ArH; J = 8.40 Hz), 
7.43 (dd, 1H, ArH; J = 8.40 Hz, 2.00 Hz), 7.52  
(d, 1H, ArH; J = 2.00 Hz), 7.53-7.56 (m, 3H, ArH),  
7.91-7.94 (m, 2H, ArH), 9.66 (s, 1H, N=CH), 12.38 
(s, 1H, NH); 
13
C NMR (DMSO-d6): δ 18.73 (2CH3), 
33.17 (CH), 55.90 (OCH3), [111.26; 120.88; 123.47; 
132.20; 142.10; 151.31] (ArC), [126.59; 127.98 (2C); 
128.48 (2C); 130.13] (ArC linked C-3), 144.55 
(Triazole C3), 151.31 (N=CH), 155.40 (Triazole C5), 
174.22 (COO); MS (70 eV): m/z (%) 115.11 (96), 
143.07 (80), 381.08 (M+1, 70), 422.17 (34), 761.27 
(2M+1, 100). 
 
General procedure for the synthesis of compounds 4 
The corresponding compound 3 (0.01 mol) was 
refluxed with acetic anhydride (15 mL) for 30 min. 
After addition of absolute ethanol (50 mL), the 
mixture was refluxed for 1 h more. Evaporation of the 
resulting solution at 40-45°C in vacuo and several 
recrystallizations of the residue from EtOH gave pure 
compounds 4a, 4b, 4d, 4e and 4g as colourless 
crystals. 
1-Acetyl-3-methyl-4-(3-methoxy-4-isobutyryloxy 
benzylideneamino)-4,5-dihydro-1H-1,2,4-triazol-5-
one, 4a: Yield 2.66 g (74%). m.p. 152°C. IR: 3068 
(C=CH), 1742, 1729 (C=O), 1584 (C=N), 1261 
(COO) cm
−1
; 
1
H NMR (DMSO-d6): δ 1.24 (d, 6H, 
2CH3; J = 6.80 Hz), 2.37 (s, 3H, CH3), 2.49 (s, 3H, 
COCH3), 2.84 (hept, 1H, CH; J = 6.80 Hz), 3.84  
(s, 3H, OCH3), 7.24 (d, 1H, ArH; J = 8.00 Hz), 7.49 
(dd, 1H, ArH; J = 8.00 Hz, 1.60 Hz), 7.61 (d, 1H, 
ArH; J = 1.60 Hz), 9.58(s, 1H, N=CH); 
13
C NMR 
(DMSO-d6): δ 11.21 (CH3), 18.72 (2CH3), 23.42 
(COCH3), 33.18 (CH), 56.08 (OCH3), [111.60; 
121.01; 123.46; 131.79; 142.35; 151.36] (ArC), 
146.70 (Triazole C3), 147.87 (N=CH), 155.24 
(Triazole C5), 166.00 (COCH3), 174.18 (COO); MS 
(70 eV): m/z (%) 115.10 (10), 361.05 (M+1, 78), 
743.24 (2M+23, 100). 
1-Acetyl-3-ethyl-4-(3-methoxy-4-isobutyryloxy 
benzylideneamino)-4,5-dihydro-1H-1,2,4-triazol-5-
one, 4b: Yield 2.72 g (72.8%). m.p. 125°C. IR: 3076 
(C=CH), 1727 (C=O), 1583 (C=N), 1247 (COO) 
cm
−1
; 
1
H NMR (DMSO-d6): δ 1.24 (d, 6H, 2CH3;  
J = 7.20 Hz), 1.25 (t, 3H, CH2CH3; J = 6.80 Hz), 2.50 
(s, 3H, COCH3), 2.77 (q, 2H, CH2CH3; J = 7.20 Hz), 
2.84 (hept, 1H, CH; J = 6.80 Hz), 3.84 (s, 3H, OCH3), 
7.24 (d, 1H, ArH; J = 8.40 Hz), 7.48 (dd, 1H, ArH; 
J = 8.40 Hz, 1.60 Hz), 7.60 (d, 1H, ArH; J = 1.60 Hz), 
9.57 (s, 1H, N=CH); 
13
C NMR (DMSO-d6): δ 9.41 
(CH2CH3), 18.52 (CH2CH3), 18.72 (2CH3), 23.43 
(COCH3), 33.18 (CH), 56.05 (OCH3), [111.61; 
120.89; 123.47; 131.82; 142.34; 151.36] (ArC), 
148.09 (Triazole C3), 150.18 (N=CH), 155.21 
(Triazole C5), 165.95 (COCH3), 174.17 (COO);  
MS (70 eV): m/z (%) 375.10 (M+1, 100), 771.27 
(2M+23, 66). 
1-Acetyl-3-benzyl-4-(3-methoxy-4-isobutyryloxy 
benzylideneamino)-4,5-dihydro-1H-1,2,4-triazol-5-
one, 4d: Yield 3.35g (76.9%). m.p. 107°C. IR: 3062 
(C=CH), 1754(C=O), 1607, 1578 (C=N), 1248 
(COO), 765 and 709 (monosubstituted benzenoid 
ring) cm
−1
; 
1
H NMR (DMSO-d6): δ 1.24 (d, 6H, 
2CH3; J = 6.80 Hz), 2.51 (s, 3H, COCH3), 2.84 (hept, 
1H, CH; J = 6.80 Hz), 3.83 (s, 3H, OCH3), 4.16  
(s, 2H, CH2Ph), 7.21 (d, 1H, ArH; J = 8.00 Hz),  
7.24-7.26 (m, 1H, ArH), 7.31-7.38 (m, 4H, ArH), 7.41  
(dd, 1H, ArH; J = 8.00 Hz, 1.60 Hz), 7.51 (d, 1H, 
ArH; J = 2.00 Hz), 9.54 (s, 1H, N=CH); 
13
C NMR 
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(DMSO-d6): δ 18.72 (2CH3), 23.51 (COCH3), 31.16 
(CH2Ph), 33.17 (CH), 56.04 (OCH3), [110.79; 121.55; 
123.42; 131.80; 142.35; 151.32] (ArC), [126.94; 
128.51(2C); 128,89(2C); 134.76] (ArC linked C-3), 
148.02 (Triazole C3), 148.23 (N=CH), 154.40 
(Triazole C5), 165.97 (COCH3), 174.18 (COO); MS 
(70 eV): m/z (%) 115.14 (48), 143.10 (30), 437.10 
(M+1, 100). 
1-Acetyl-3-p-methylbenzyl-4-(3-methoxy-4-
isobutyryloxybenzylideneamino)-4,5-dihydro-1H-1,2, 
4-triazol-5-one, 4e: Yield 3.10 g (68.9 %). m.p. 
118°C. IR: 3079 (C=CH), 1749, 1725 (C=O), 1610, 
1576 (C=N), 1250 (COO), 844 (1,4-disubstituted 
benzenoid ring) cm
−1
; 
1
H NMR (DMSO-d6): δ 1.24 
(d, 6H, 2CH3; J = 7.20 Hz), 2.25 (s, 3H, PhCH3), 2.51 
(s, 3H, COCH3), 2.84 (hept, 1H, CH; J = 6.80 Hz), 
3.84 (s, 3H, OCH3), 4.10 (s, 2H, CH2Ph), 7.12 (d, 2H, 
ArH; J = 8.00 Hz), 7.22 (d, 1H, ArH; J = 8.40 Hz), 
7.26 (d, 2H, ArH; J = 8.00 Hz), 7.41 (dd, 1H, ArH;  
J = 8.40 Hz, 2.00 Hz), 7.51 (d, 1H, ArH; J = 2.00 Hz), 
9.54 (s, 1H, N=CH); 
13
C NMR (DMSO-d6): δ 18.12 
(2CH3), 20.59 (PhCH3), 23.51 (COCH3), 30.78 (CH2Ph), 
33.17 (CH), 56.01 (OCH3), [110.76; 121.56; 123.42; 
131.61; 142.34; 151.32] (ArC), [128.77(2C); 
129.07(2C); 131.82; 136.07] (ArC linked C-3), 148.01 
(Triazole C3), 148.37 (N=CH), 154.34 (Triazole C5), 
165.77 (COCH3), 174.19 (COO); MS (70 eV): m/z (%) 
115.10 (84), 143.16 (18), 451.17 (M+1, 100). 
1-Acetyl-3-p-chlorobenzyl-4-(3-methoxy-4-
isobutyryloxybenzylideneamino)-4,5-dihydro-1H-1,2, 
4-triazol-5-one, 4g: Yield 3.52 g (75 %). m.p. 156°C. 
IR: 3076 (C=CH), 1751, 1720 (C=O), 1610, 1578 
(C=N), 1244 (COO), 862 (1,4-disubstituted benzenoid 
ring) cm
−1
; 
1
H NMR (DMSO-d6): δ 1.24 (d, 6H, 
2CH3; J = 7.20 Hz), 2.51 (s, 3H, COCH3), 2.84 (hept, 
1H, CH; J = 7.20 Hz), 3.83 (s, 3H, OCH3), 4.18 (s, 
2H, CH2Ph), 7.22 (d, 1H, ArH; J = 8.00 Hz),  
7.38-7.43 (m, 5H, ArH), 7.50 (d, 1H, ArH; J = 1.60 
Hz), 9.55 (s, 1H, N=CH); 
13
C NMR (DMSO-d6): δ 
18.72 (2CH3), 23.50 (COCH3), 30.47 (CH2Ph), 33.17 
(CH), 56.05 (OCH3), [110.83; 121.54; 123.44; 
131.77; 142.37; 151.34] (ArC), [128.44 (2C); 130.83 
(2C); 131.66; 133.80] (ArC linked C-3), 147.93 
(Triazole C3), 148.01 (N=CH), 154.49 (Triazole C5), 
165.95 (COCH3), 174.19 (COO);
 
MS (70 eV): m/z 
(%) 115.11 (84), 143.07 (100), 471.11 (M+1, 38). 
 
General procedure for the synthesis of compounds 5 
The corresponding compound 3 (0.01 mol) was 
dissolved in 100 mL of ethanol followed by addition 
of morpholine (0.015 mol) and formaldehyde (0.02 
mol). The reaction mixture was refluxed for 3 h. After 
standing at RT overnight, the solid was filtered and 
crystallized from ethanol. The solid was recrystallized 
from the same solvent and purified by drying in vacuo 
to obtain pure compounds 5 as colourless crystals. 
1-(Morpholine-4-yl-methyl)-3-methyl-4-(3-
methoxy-4-isobutyryloxybenzylidene-amino)-4,5-
dihydro-1H-1,2,4-triazol-5-one, 5a: Yield 3.20 g 
(76.9%). m.p. 136°C. IR: 3067 (C=CH), 1762, 1691 
(C=O), 1601, 1577 (C=N), 1237 (COO) cm
−1
; 
1
H NMR (DMSO-d6): δ 1.24 (d, 6H, 2CH3; J = 7.20 Hz), 
2.32 (s, 3H, CH3), 2.58 (t, 4H, CH2NCH2; J = 4.40 Hz), 
2.84 (hept, 1H, CH; J = 7.20 Hz), 3.56 (t, 4H, 
CH2OCH2; J = 4.40 Hz), 3.84 (s, 3H, OCH3), 4.54  
(s, 2H, NCH2), 7.23 (d, 1H, ArH; J = 8.40 Hz), 7.46 
(dd, 1H, ArH; J = 8.40 Hz, 2.00 Hz), 7.59 (d, 1H, 
ArH; J = 1.60 Hz), 9.69 (s, 1H, N=CH); 
13
C NMR  
(DMSO-d6): δ 10.95 (CH3), 18.73 (2CH3), 33.18 
(CH), 49.97 (CH2NCH2), 56.06 (OCH3), 65.92 
(NCH2), 66.05 (CH2OCH2), [111.50; 120.69; 123.40; 
132.13; 142.08; 151.32] (ArC), 143.12 (Triazole C3), 
150.23 (N=CH), 153.79 (Triazole C5), 174.20 (COO); 
MS (70 eV): m/z (%) 118.11 (24), 129.09 (24), 132.13 
(38), 418.13 (M+1, 100), 459.13 (6). 
1-(Morpholine-4-yl-methyl)-3-ethyl-4-(3-
methoxy-4-isobutyryloxybenzylidene-amino)-4,5-
dihydro-1H-1,2,4-triazol-5-one, 5b: Yield 3.33 g 
(77.4%). m.p. 154°C. IR: 3077 (C=CH), 1763, 1692 
(C=O), 1611, 1578 (C=N), 1235 (COO) cm
−1
; 
1
H NMR 
(DMSO-d6): δ 1.23 (d, 6H, 2CH3; J = 7.20 Hz), 1.24 (t, 
3H, CH2CH3; J=6.80 Hz), 2.59 (t, 4H, CH2NCH2;  
J = 4.40 Hz), 2.74 (q, 2H, CH2CH3; J = 7.60 Hz), 2.84 
(hept, 1H, CH; J = 7.20 Hz), 3.56 (t, 4H, CH2OCH2;  
J = 4.40 Hz), 3.84 (s, 3H, OCH3), 4.55 (s, 2H, NCH2), 
7.23 (d, 1H, ArH; J = 8.00 Hz), 7.46 (dd, 1H, ArH;  
J = 8.00 Hz, 1.60 Hz), 7.58 (d, 1H, ArH; J = 1.60 Hz), 
9.69 (s, 1H, N=CH); 
13
C NMR (DMSO-d6): δ 9.96 
(CH2CH3), 18.38 (CH2CH3), 18.72 (2CH3), 33.18 
(CH), 49.98 (CH2NCH2), 56.03 (OCH3), 65.96 
(NCH2), 66.03 (CH2OCH2), [111.52; 120.56; 123.40; 
132.17; 142.07; 151.32] (ArC), 146.83 (Triazole C3), 
150.35 (N=CH), 153.75 (Triazole C5), 174.19 (COO); 
MS (70 eV): m/z (%) 118.11 (12), 129.10 (44), 132.13 
(28), 432.15 (M+1, 100). 
1-(Morpholine-4-yl-methyl)-3-benzyl-4-(3-
methoxy-4-isobutyryloxybenzylidene-amino)-4,5-
dihydro-1H-1,2,4-triazol-5-one, 5d: Yield 3.58g 
(72.6%). m.p. 131°C. IR: 3068 (C=CH), 1758, 1696 
(C=O), 1596, 1578 (C=N), 1246 (COO), 747 and 697 
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(monosubstituted benzenoid ring) cm
−1
; 
1
H NMR 
(DMSO-d6): δ 1.24 (d, 6H, 2CH3; J = 7.20 Hz), 2.60 
(t, 4H, CH2NCH2; J = 4.40 Hz), 2.84 (hept, 1H, CH;  
J = 7.20 Hz), 3.57 (t, 4H, CH2OCH2; J = 4.40 Hz), 
3.83 (s, 3H, OCH3), 4.12 (s, 2H, CH2Ph), 4.59 (s, 2H, 
NCH2), 7.21 (d, 1H, ArH; J = 8.00 Hz), 7.23-7.25  
(m, 1H, ArH), 7.31-7.36 (m, 4H, ArH), 7.38 (dd, 1H, 
ArH; J = 8.00 Hz, 1.60 Hz), 7.49 (d, 1H, ArH;  
J = 1.60 Hz), 9.64 (s, 1H, N=CH); 
13
C NMR (DMSO-d6): 
δ 18.72 (2CH3), 31.05 (CH2Ph), 33.17 (CH), 50.00 
(CH2NCH2), 56.00 (OCH3), 66.04 (NCH2+ 
CH2OCH2), [110.68; 121.22; 123.34; 132.11; 142.10; 
151.29] (ArC), [126.77; 128.50(2C); 128,63(2C); 
135.70] (ArC linked C-3), 144.91 (Triazole C3), 
150.24 (N=CH), 153.07 (Triazole C5), 174.18 (COO); 
MS (70 eV): m/z (%) 118.11 (40), 129.10 (64), 132.13 
(60), 494.20 (M+1, 100). 
1-(Morpholine-4-yl-methyl)-3-p-methylbenzyl-4-
(3-methoxy-4-isobutyryloxy-benzylideneamino)-
4,5-dihydro-1H-1,2,4-triazol-5-one, 5e: Yield 3.69 g 
(72.8 %). m.p. 122°C. IR: 3072 (C=CH), 1756, 1695 
(C=O), 1613, 1579 (C=N), 1243 (COO), 860 (1,4-
disubstituted benzenoid ring) cm
−1
; 
1
H NMR (DMSO-
d6): δ 1.24 (d, 6H, 2CH3; J = 6.80 Hz), 2.24 (s, 3H, 
PhCH3), 2.59 (t, 4H, CH2NCH2; J = 4.40 Hz), 2.84 
(hept, 1H, CH; J = 6.80 Hz), 3.57 (t, 4H, CH2OCH2;  
J = 4.40 Hz), 3.84 (s, 3H, OCH3), 4.06 (s, 2H, 
CH2Ph), 4.58 (s, 2H, NCH2),7.12 (d, 2H, ArH;  
J = 8.00 Hz), 7.21 (d, 1H, ArH; J = 8.00 Hz), 7.23  
(d, 2H, ArH; J = 8.00 Hz), 7.39 (dd, 1H, ArH;  
J = 8.40 Hz, 1.60 Hz), 7.50 (d, 1H, ArH; J = 1.60 Hz), 
9.64 (s, 1H, N=CH); 
13
C NMR (DMSO-d6): δ 18.72 
(2CH3), 20.56 (PhCH3), 30.65 (CH2Ph), 33.17 (CH), 
49.99 (CH2NCH2), 55.98 (OCH3), 66.03 (NCH2+ 
CH2OCH2), [110.67; 121.23; 123.36; 132.13; 142.08; 
151.28] (ArC), [128.52(2C); 129.07(2C); 132.57; 
135.88] (ArC linked C-3), 145.06 (Triazole C3), 
150.24 (N=CH), 153.01 (Triazole C5), 174.20 (COO); 
MS (70 eV): m/z (%) 118.11 (36), 129.10 (56), 132.13 
(36), 508.21 (M+1, 100). 
1-(Morpholine-4-yl-methyl)-3-p-chlorobenzyl-4-(3-
methoxy-4-isobutyryloxy-benzylideneamino)-4,5-
dihydro-1H-1,2,4-triazol-5-one, 5g: Yield 3.89 g (73.8 
%). m.p. 125°C. IR: 3062 (C=CH), 1763, 1697 (C=O), 
1594, 1576 (C=N), 1245 (COO), 860 (1,4-disubstituted 
benzenoid ring) cm
−1
; 
1
H NMR (DMSO-d6): δ 1.24  
(d, 6H, 2CH3; J = 7.20 Hz), 2.59 (t, 4H, CH2NCH2;  
J = 4.40 Hz), 2.84 (hept, 1H, CH; J = 6.80 Hz), 3.57  
(t, 4H, CH2OCH2; J = 4.40 Hz), 3.83 (s, 3H, OCH3), 
4.13 (s, 2H, CH2Ph), 4.58 (s, 2H, NCH2), 7.21 (d, 1H, 
ArH; J = 8.00 Hz), 7.36-7.42 (m, 5H, ArH), 7.49 (d, 1H, 
ArH; J = 2.00 Hz), 9.65 (s, 1H, N=CH); 
13
C NMR 
(DMSO-d6): δ 18.72 (2CH3), 30.51 (CH2Ph), 33.17 
(CH), 49.97 (CH2NCH2), 56.01 (OCH3), 66.03 (NCH2), 
66.09 (CH2OCH2), [110.77; 121.21; 123.37; 132.06; 
142.13; 151.30] (ArC), [128.45 (2C); 130.58 (2C); 
131.49; 134.70] (ArC linked C-3), 144.59 (Triazole C3), 
150.33 (N=CH), 153.24 (Triazole C5), 174.19 (COO); 
MS (70 eV): m/z (%) 118.11 (48), 129.10 (84), 132.10 
(48), 528.18 (M+1, 100). 
 
General procedure for the synthesis of compounds 6 
The corresponding compound 3 (0.01 mol) was 
dissolved in 100 mL of ethanol followed by addition 
of 1-methylpiperazin (0.015 mol) and formaldehyde 
(0.02 mol). The reaction mixture was refluxed for 3 
hours. After standing at RT overnight, the solid was 
filtered and crystallized from ethanol. The solid was 
recrystallized from the same solvent and purified by 
drying in vacuo to obtain pure compounds 6 as 
colourless crystals. 
1-(1-Methylpiperazin-4-yl-methyl)-3-methyl-4-
(3-methoxy-4-isobutyryloxy-benzylideneamino)-
4,5-dihydro-1H-1,2,4-triazol-5-one, 6a: Yield 3.88 g 
(90.4%). m.p. 88°C. IR: 3071 (C=CH), 1756, 1691 
(C=O), 1600, 1579 (C=N), 1247 (COO) cm
−1
; 
1
H NMR (DMSO-d6): δ 1.24 (d, 6H, 2CH3), 2.15  
(s, 3H, NCH3), 2.30 (s, 3H, CH3), 2.34 (m, 4H, 
(2CH2; J = 4.40 Hz), 2.61 (m, 4H, 2CH2), 2.85 (hept, 
1H, CH; J = 6.80 Hz), 3.85 (s, 3H, OCH3), 4.55  
(s, 2H, NCH2), 7.23 (d, 1H, ArH; J = 8.00 Hz), 7.47 
(dd, 1H, ArH; J = 8.00 Hz, 2.00 Hz), 7.60 (d, 1H, 
ArH; J = 2.00 Hz), 9.71 (s, 1H, N=CH); 
13
C NMR 
(DMSO-d6): δ 10.90 (CH3), 18.71 (2CH3), 33.18 
(CH), 45.49 (NCH3), 49.37 (2CH2), 54.60 (2CH2), 
56.02 (OCH3), 65.72 (NCH2), [111.46; 120.65; 
123.65; 132.14; 142.82; 151.31] (ArC), 143.79 
(Triazole C3), 150.06 (N=CH), 153.63 (Triazole C5), 
174.16 (COO); MS (70 eV): m/z (%) 113.10 (38), 
431.13 (M+1, 100). 
1-(1-Methylpiperazin-4-yl-methyl)-3-ethyl-4-(3-
methoxy-4-isobutyryloxy-benzylideneamino)-4,5-
dihydro-1H-1,2,4-triazol-5-one, 6b: Yield 3.49 g 
(78.8%). m.p. 116°C; IR: 3065 (C=CH), 1758, 1791 
(C=O), 1611, 1579 (C=N), 1235 (COO), 749  
(1,2-disubstituted benzenoid ring) cm
−1
; 
1
H NMR 
(DMSO-d6): δ 1.23 (t, 3H, CH2CH3; J = 7.20 Hz), 
1.24 (d, 6H, 2CH3; J = 7.20 Hz), 2.14 (s, 3H, NCH3), 
2.30 (m, 4H, 2CH2), 2.60 (m, 4H, 2CH2), 2.74 (q, 2H, 
CH2CH3; J = 7.60 Hz), 2.84 (hept, 1H, CH; J = 7.20 
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Hz), 3.84 (s, 3H, OCH3), 4.55 (s, 2H, NCH2), 7.22  
(d, 1H, ArH; J = 8.00 Hz), 7.46 (dd, 1H, ArH; J = 
8.00 Hz, 1.60 Hz), 7.58 (d, 1H, ArH; J = 1.60 Hz), 
9.69 (s, 1H, N=CH); 
13
C NMR (DMSO-d6): δ 9.99 
(CH2CH3), 18.72 (CH2CH3), 18.88 (2CH3), 33.18 (CH), 
45.67 (NCH3), 49.39 (2CH2), 54.54 (2CH2), 56.02 
(OCH3), 65.75 (NCH2), [111.52; 120.54; 123.39; 
132.18; 142.05; 151.31] (ArC), 146.69 (Triazole C3), 
150.31 (N=CH), 153.67 (Triazole C5), 174.19 (COO); 
MS (70 eV): m/z (%) 113.11 (32), 445.16 (M+1, 100). 
1-(1-Methylpiperazin-4-yl-methyl)-3-benzyl-4-
(3-methoxy-4-isobutyryloxy-benzylideneamino)-
4,5-dihydro-1H-1,2,4-triazol-5-one, 6d: Yield 4.37g 
(86.34%). m.p. 101°C. IR: 3082 (C=CH), 1758, 1694 
(C=O), 1608, 1575 (C=N), 1237 (COO), 747, 698 
(monosubstituted benzenoid ring) cm
−1
; 
1
H NMR 
(DMSO-d6): δ 1.23 (d, 6H, 2CH3; J = 7.20 Hz), 2.14 
(s, 3H, NCH3), 2.31 (m, 4H, 2CH2), 2.62 (m, 4H, 
2CH2), 2.84 (hept, 1H, CH; J = 7.20 Hz), 3.83 (s, 3H, 
OCH3), 4.11 (s, 2H, CH2Ph), 4.59 (s, 2H, NCH2), 
7.22-7.27 (m, 2H, ArH), 7.30-7.36 (m, 4H, ArH), 7.38 
(dd, 1H, ArH; J = 8.40 Hz, 1.60 Hz), 7.49 (d, 1H, 
ArH; J = 1.60 Hz), 9.65 (s, 1H, N=CH); 
13
C NMR 
(DMSO-d6): δ 18.72 (2CH3), 31.02 (CH2Ph), 33.17 
(CH), 45.67 (NCH3), 49.40 (2CH2), 54.49 (2CH2), 
55.99 (OCH3), 65.98 (NCH2), [110.69; 121.20; 
123.34; 132.13; 142.09; 151.26] (ArC), [126.76; 
128.45(2C); 128,66(2C); 135.73] (ArC linked C-3), 
144.77 (Triazole C3), 150.20 (N=CH), 153.00 
(Triazole C5), 174.18 (COO); MS (70 eV): m/z (%) 
113.12 (30), 507.20 (M+1, 100). 
1-(1-Methylpiperazin-4-yl-methyl)-3-p-methylbenzyl-
4-(3-methoxy-4-isobutyryl-oxybenzylideneamino)-
4,5-dihydro-1H-1,2,4-triazol-5-one, 6e: Yield 3.77 g 
(72.55 %). m.p. 149°C. IR: 3078 (C=CH), 1753, 1696 
(C=O), 1613, 1579 (C=N), 1239 (COO), 868 (1,4-
disubstituted benzenoid ring) cm
−1
; 
1
H NMR (DMSO-
d6): δ 1.24 (d, 6H, 2CH3; J = 7.20 Hz), 2.13 (s, 3H, 
NCH3), 2.24 (s, 3H, PhCH3), 2.30 (m, 4H, 2CH2), 
2.60 (m, 4H, 2CH2), 2.84 (hept, 1H, CH; J = 6.80 Hz), 
3.83 (s, 3H, OCH3), 4.05 (s, 2H, CH2Ph), 4.58 (s, 2H, 
NCH2), 7.12 (d, 2H, ArH; J = 8.00 Hz), 7.20 (d, 2H, 
ArH; J = 8.00 Hz), 7.22 (d, 1H, ArH; J = 8.00 Hz), 
7.38 (dd, 1H, ArH; J = 8.00 Hz, 1.60 Hz), 7.50  
(d, 1H, ArH; J = 2.00 Hz), 9.64 (s, 1H, N=CH); 
13
C NMR (DMSO-d6): δ 18.73 (2CH3), 20.56 
(PhCH3), 30.65 (CH2Ph), 33.18 (CH), 45.74 (NCH3), 
49.45 (2CH2), 54.53 (2CH2), 55.99 (OCH3),  
65.88 (NCH2), [110.71; 121.21; 123.36; 132.15; 
142.08; 151.29] (ArC), [128.50 (2C); 129.07 (2C); 
132.60; 135.87] (ArC linked C-3), 144.92 (Triazole 
C3), 150.20 (N=CH), 152.98 (Triazole C5), 174.20  
(COO); MS (70 eV): m/z (%) 113.12 (30), 521.24 
(M+1, 100). 
1-(1-Methylpiperazin-4-yl-methyl)-3-p-chlorobenzyl- 
4-(3-methoxy-4-isobutyryloxybenzylideneamino)-
4,5-dihydro-1H-1,2,4-triazol-5-one, 6g: Yield 3.97 g 
(73.48 %). m.p. 107°C. IR: 3069 (C=CH), 1758, 1697 
(C=O), 1611, 1577 (C=N), 1236 (COO), 868 (1,4-
disubstituted benzenoid ring) cm
−1
; 
1
H NMR (DMSO-
d6): δ 1.24 (d, 6H, 2CH3; J = 7.20 Hz), 2.13 (s, 3H, 
NCH3), 2.29 (m, 4H, 2CH2), 2.60 (m, 4H, 2CH2), 2.84 
(hept, 1H, CH; J = 7.20 Hz), 3.83 (s, 3H, OCH3), 4.13 
(s, 2H, CH2Ph), 4.57 (s, 2H, NCH2), 7.21 (d, 2H, 
ArH; J = 8.00 Hz), 7.35-7.41 (m, 2H, ArH), 7.38  
(d, 2H, ArH; J = 8.00 Hz), 7.48 (d, 1H, ArH;  
J = 1.60 Hz), 9.65 (s, 1H, N=CH); 
13
C NMR  
(DMSO-d6): δ 18.72 (2CH3), 30.34 (CH2Ph), 33.17 
(CH), 45.73 (NCH3), 49.42 (2CH2), 54.51 (2CH2), 
56.01 (OCH3), 65.92 (NCH2), [110.76; 121.19; 
123,37; 132.08; 142.10; 151.29] (ArC), [128.46 (2C); 
130.56 (2C); 131.48; 134.73] (ArC linked C-3), 
144,45 (Triazole C3), 150,18 (N=CH), 153,17 
(Triazole C5), 174.20 (COO); MS (70 eV): m/z (%) 
113.12 (98), 541.19 (M+1, 100). 
 
Antimicrobial activity 
All bacterial and yeast strains were obtained from 
the company of Microbiological Environmental 
Protection Laboratories (France) and were as follows: 
Bacillus subtilis (ATCC 11774), Bacillus cereus 
(ATCC 11778), Staphylococcus aureus (ATCC 6538), 
Escherichia coli (ATCC 25922), Pseudomonas 
aeruginosa (ATCC 27853), Klebsiella pneumonia 
(ATCC 4352). Simple susceptibility screening test 
using agar well diffusion method was used
31,32
. All the 
newly synthesized compounds were weighed and 
dissolved in dimethylsulphoxide (DMSO) to prepare 
extract stock solution of 1 mg/mL. 
Each microorganism was suspended in Mueller-
Hinton Broth and diluted to 106 colony forming unit 
(cfu) per mL. They were “flood-inoculated” onto the 
surface of Mueller Hinton Agar and then dried. Five-
millimeter diameter wells were cut from the agar 
using a sterile cork-borer, and 250–5000 μg/50 μL of 
the chemical substances were delivered into the wells. 
The plates were incubated for 18 h at 35°C. 
Antimicrobial activity was evaluated by measuring 
the zone of inhibition against the test organism. 
Ampicillin (10 μg) for bacteria, streptomycin and 
INDIAN J. CHEM., SEC B, FEBRUARY 2020 
 
 
282 
fluconazole (5 μg) for yeast were used as positive 
controls, DMSO was used as solved control. 
 
Antioxidant Activity: Chemicals 
Butylated hydroxytoluene (BHT) was obtained 
from E. Merck. Ferrous chloride, α-tocopherol, 1,1-
diphenyl-2-picryl-hydrazyl (DPPH
.
), 3-(2-pyridyl)-
5,6-bis(phenylsulfonic acid)-1,2,4-triazine (ferrozine), 
butylated hydroxyanisole (BHA), ethylenedi- 
aminetetraacetic acid (EDTA) and trichloroacetic acid 
(TCA) were obtained from Sigma–Aldrich. 
 
Reducing Power 
The reducing power of the synthesized compounds 
was determined according to the method of Oyaizu
33
 
as explained in the literature
14
. 
 
Free Radical Scavenging Activity 
Free radical scavenging activity of compounds was 
measured by DPPH
.
, using the method of Blois
34
 as 
explained in the literature
14
. 
 
Metal Chelating Activity 
The chelation of ferrous ions by the synthesized 
compounds and standards were estimated by the method 
of Dinis et al.
35
 as explained in the literature
14
. 
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